SITC 2024: Humanized HER2-expressing tumor cells established syngeneic models for evaluating HER2 antibody-drug conjugate (ADC) therapy

SITC2024: The paring of CD200 humanized cancer cells with CD200 and CD200R double humanized mice for the preclinical evaluation of the combination of anti-human CD200 antibodies and immune checkpoint drugs

BCG014: A CDH3-Targeting ADC with a Novel TOPO1 Inhibitor Payload

World ADC San Diego2024: Development of a novel bispecific ADC targeting SEZ6 and B7H3 for small cell lung cancer (SCLC)

ESDR2024：BCG028, a novel Fc-optimized fully human biparatopic OX40 antagonist for treating atopic dermatitis

ASCO 2024: A phase II, multi-center, open-label study to evaluate the safety and efficacy of YH003 in combination with Toripalimab (anti-PD-1 mAb) in patients with unresectable/metastatic pancreatic ductal adenocarcinoma

IO Summit Europe 2024: Fully human conditional agonist 4-1BB×CD40 bispecific antibody exhibits potent in vitro and in vivo efficacy

Festival of Biologics 2024: Generation of a TAA Antibody Library to Support the Development of Antibody-Drug Conjugates (ADC)

AACR 2024: Identification of fully human CCR8 antibodies that demonstrate excellent ADCC function, potent blocking activity, and robust anti-tumor immune responses